Press Release

RICHMOND, Va.--(BUSINESS WIRE)-- Altria Group, Inc. (NYSE: MO) today reports our 2025 fourth-quarter and full-year business results and provides our guidance for 2026 full-year adjusted diluted earnings per share (EPS).

“2025 was a year of continued momentum for Altria, marked by strong financial performance, strategic progress across our smoke-free portfolio, new relationships in support of our long-term growth goals and significant cash returns to shareholders,” said Billy Gifford, Altria’s Chief Executive Officer. “For the full year, we grew adjusted diluted earnings per share by 4.4% and returned $8 billion to shareholders through dividends and share repurchases combined.”

“We expect to deliver 2026 full-year adjusted diluted EPS in a range of $5.56 to $5.72. This range represents a growth rate of 2.5% to 5.5% from a base of $5.42 in 2025.”

Altria Headline Financials¹

¹ “Adjusted” financial measures presented in this release exclude the impact of special items. See “Basis of Presentation” for more information and see the schedules to this press release for reconciliations to corresponding GAAP measures.

² Prior period amounts have been recast to conform with current period presentation for amortization expense associated with definite-lived intangible assets (amortization of intangibles) that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures. For more information, see 2026 Full-Year Guidance below.

As previously announced, a conference call with the investment community and news media will be webcast on January 29, 2026 at 9:00 a.m. Eastern Time. Access to the webcast is available at www.altria.com/webcasts.

Cash Returns to Shareholders

Share Repurchase Program

• In the fourth quarter, we repurchased 4.8 million shares at an average price of $59.56, for a total cost of $288 million. For the full year, we repurchased 17.1 million shares at an average price of $58.50, for a total cost of $1 billion.
• As of December 31, 2025, we had $1 billion remaining under our $2 billion share repurchase program, which expires on December 31, 2026. Share repurchases depend on marketplace conditions and other factors, and the program remains subject to the discretion of our Board of Directors (Board).

Dividends

• We paid dividends of $1.8 billion and $7.0 billion in the fourth quarter and full year, respectively.

Smoke-Free Portfolio Update

• In December 2025, Helix received marketing authorizations from the FDA for on! PLUS products in mint, wintergreen and tobacco, each with 6 milligram and 9 milligram nicotine strengths. The 12 milligram nicotine strength variants remain under FDA review.
• In November 2025, Helix submitted premarket tobacco product applications for on! PLUS products in six additional flavor varieties across three nicotine strengths.

Optimize & Accelerate Initiative

• In October 2024, we announced a multi-phase Optimize & Accelerate initiative (Initiative) designed to modernize our ways of working and accelerate progress toward our Vision and 2028 Enterprise Goals. At that time, we estimated the Initiative’s initial phases would deliver at least $600 million in cumulative cost savings over five years (excluding exit and implementation costs), with plans to reinvest those savings in our business.
• The Initiative is performing in line with our original expectations, and we are pleased with the progress made in the first year. In 2025, we began modernizing our ways of working, which enabled increased speed, efficiency and effectiveness across the organization. We are now adding the final phases of the Initiative and continue to expect to deliver cumulative savings of at least $600 million by the end of 2029.
• The savings estimates exclude estimated pre-tax charges of approximately $175 million, updated from our prior estimate of approximately $125 million. This updated estimate incorporates charges associated with the final phases of the Initiative.

2028 Enterprise Goals

Our 2028 Enterprise Goals and progress through 2025 are listed below.

Corporate

• Deliver a mid-single digits adjusted diluted EPS compounded annual growth rate (CAGR) in 2028 from a $4.87 ¹ base in 2022.
  • Through 2025, we delivered a reported diluted EPS CAGR of 8.9% and an adjusted diluted EPS CAGR of 3.6% ¹ from the 2022 base.
• A progressive dividend goal targeting mid-single digits dividend per share growth annually through 2028.
  • In 2025, we increased our dividend by 3.9%, marking the 60th increase in the past 56 years. Future dividend payments remain subject to the discretion of our Board.
• Target a debt-to-Consolidated EBITDA ratio of approximately 2.0x.
  • At year end, our debt-to-Consolidated Net Earnings ratio was 3.7x and our debt-to-Consolidated EBITDA ratio was 2.0x ¹.
• Maintain our leadership position in the U.S. tobacco space.
  • On the strength of our companies’ leading core tobacco brands, Marlboro, Copenhagen and Black & Mild, and our innovative oral nicotine portfolio, including on! and on! PLUS, we estimate that we achieved an industry-leading share of the U.S. nicotine space in 2025.
• Maintain a total adjusted operating companies income (OCI) margin of at least 60% in each year through 2028.
  • For 2025, our total reported OCI margin was 51.1% and our total adjusted OCI margin was 62.4% ¹.

U.S. Smoke-Free Portfolio

• Due to ongoing market disruption caused by e-vapor products that have evaded the regulatory process (illicit), we continue to reassess our smoke-free goals and expect to provide updated goals when we have more clarity on how the legitimate e-vapor market may evolve.
• We remain steadfast in our commitment to our Vision and to building a portfolio of FDA-authorized smoke-free products for adult smokers and ANCs currently using smoke-free products.

Long-Term Growth

• Compete internationally in the top innovative oral tobacco markets and develop a pathway to participate in heated tobacco and e-vapor markets.
  • on! and on! PLUS are competing internationally via e-commerce and at select retail locations in Sweden and the United Kingdom.
  • FUMi is now competing across 40,000 retail locations in seven international markets, supported by a differentiated portfolio with 12 flavor offerings.
• Enter non-nicotine categories with broad commercial distribution of at least five products by 2028.
  • We continue to test a variety of internally- and partner-developed concepts and products to garner consumer and marketplace insights to inform our non-nicotine strategies. Our efforts remain concentrated on products with the potential to enhance energy, focus, stress relief and relaxation.
  • Altria Group Distribution Company is providing certain sales and distribution services to Proper Wild, which achieved broad commercial distribution to over 25,000 stores in 2025.

¹ See “Basis of Presentation” for more information on these non-GAAP financial measures. Reconciliations of these non-GAAP financial measures are included in Schedules 14, 15 and 16.

2026 Full-Year Guidance

We expect to deliver 2026 full-year adjusted diluted EPS in a range of $5.56 to $5.72, representing a growth rate of 2.5% to 5.5% from a base of $5.42 in 2025. We expect 2026 adjusted diluted EPS growth to be weighted to the second half of the year, reflecting a progressive increase in cigarette import and export activity over the course of the year.

Our guidance contemplates:

(i) planned investments to support our contract manufacturing capabilities;

(ii) limited impact on combustible and e-vapor product volumes from illicit enforcement efforts; and

(iii) that NJOY ACE does not return to the marketplace in 2026.

Our 2026 full-year adjusted diluted EPS guidance range includes planned investments in support of our Vision, including cost savings generated from our Initiative, such as (i) marketplace activities in support of our smoke-free products and (ii) continued smoke-free product research, development and regulatory preparation expenses.

We expect our 2026 full-year adjusted effective tax rate to be in a range of 22.5% to 23.5%, our 2026 capital expenditures to be between $300 million and $375 million, which includes planned investments to support contract manufacturing capabilities and innovative products, and our 2026 depreciation and amortization expenses to be approximately $225 million.

Our full-year adjusted diluted EPS guidance range and full-year forecast for our adjusted effective tax rate exclude the impact of certain income and expense items that our management believes are not part of underlying operations. These items may include, for example, loss on early extinguishment of debt, restructuring charges, asset impairment charges, acquisition, disposition and integration-related items, equity investment-related special items, certain income tax items, charges associated with tobacco and health and certain other litigation items, resolutions of certain non-participating manufacturer (NPM) adjustment disputes under the Master Settlement Agreement (NPM Adjustment Items) and amortization of intangibles. Beginning in the first quarter of 2025, we changed our treatment of our amortization of intangibles, which was previously included in our adjusted results, including adjusted net earnings and adjusted diluted EPS, and now treat this expense as a special item and exclude it from our adjusted results. Net revenues generated from these definite-lived intangible assets during the periods presented, if applicable, are included in our adjusted financial measures. See Table 1 below for the income and expense items for the full-year 2025.

Our management cannot estimate on a forward-looking basis the impact of certain income and expense items, including those items noted in the preceding paragraph, on our reported diluted EPS or our effective tax rate because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable. As a result, we do not provide a corresponding U.S. generally accepted accounting principles (GAAP) measure for, or reconciliation to, our adjusted diluted EPS guidance or our adjusted effective tax rate forecast.

ALTRIA GROUP, INC.

See “Basis of Presentation” below for an explanation of financial measures and reportable segments discussed in this release.

Financial Performance

Fourth Quarter

• Net revenues decreased 2.1% to $5.8 billion, primarily driven by lower net revenues in the smokeable products segment. Revenues net of excise taxes decreased 0.5% to $5.1 billion.
• Reported diluted EPS decreased 63.1% to $0.66, primarily driven by 2025 non-cash impairment charges in our e-vapor products reportable segment (see “ Basis of Presentation” for more information on our reportable segments) and unfavorable income tax items, partially offset by lower costs related to our Initiative.
• Adjusted diluted EPS was unchanged at $1.30, driven by a lower adjusted tax rate and fewer shares outstanding, offset by lower adjusted OCI.

Full Year

• Net revenues decreased 3.1% to $23.3 billion, primarily driven by lower net revenues in the smokeable products segment. Revenues net of excise taxes decreased 1.5% to $20.1 billion.
• Reported diluted EPS decreased 37.0% to $4.12, primarily driven by the 2024 gain on the sale of the IQOS Tobacco Heating System commercialization rights, unfavorable income tax items and lower reported OCI, which includes higher non-cash impairments. These factors were partially offset by fewer shares outstanding and lower change in the fair value of contingent payments associated with the acquisition of NJOY.
• Adjusted diluted EPS increased 4.4% to $5.42, primarily driven by higher adjusted OCI, fewer shares outstanding and a lower adjusted tax rate, partially offset by lower net periodic benefit income, excluding service cost, and higher financing costs.

¹ Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures. For further discussion of our special items, see the 2026 Full-Year Guidance section above.

Note: For details of pre-tax, tax and after-tax amounts, see Schedules 6, 7, 8 and 9.

Special Items

The EPS impact of the following special items is shown in Table 1 and Schedules 6, 7, 8 and 9.

Acquisition and Disposition-Related Items

For the full-year 2025, we recorded net pre-tax expense items of $76 million (or $0.04 per share), including $51 million related to the International Trade Commission’s (ITC) exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States. The expenses related to the ITC orders were partially offset by insurance recoveries from insurance contracts associated with the acquisition of NJOY. Also included is a non-cash, pre-tax charge of $25 million related to a change in the fair value of the contingent payments associated with the acquisition of NJOY.

For the full-year 2024, we recorded net pre-tax income of $2.5 billion (or $1.08 per share) of acquisition and disposition-related items, primarily related to a pre-tax gain of $2.7 billion upon the assignment of the IQOS Tobacco Heating System commercialization rights to Philip Morris International Inc. in April 2024, partially offset by pre-tax expenses associated with the acquisition of NJOY, including a pre-tax charge of $140 million related to a change in the fair value of the contingent payments.

Asset Impairment, Exit and Implementation Costs

For the fourth quarter and full-year 2025, we recorded pre-tax charges of $1.3 billion (or $0.61 per share) and $2.2 billion (or $1.14 per share), respectively, primarily due to non-cash impairments of the e-vapor reporting unit goodwill and definite-lived intangible assets in our e-vapor products reportable segment.

In the fourth quarter of 2024, we recorded pre-tax charges of $68 million (or $0.03 per share) for employee separation costs and implementation costs related to our Initiative. For the full-year 2024, we recorded pre-tax charges of $422 million (or $0.18 per share) for a non-cash impairment of the Skoal trademark and employee separation costs and implementation costs related to our Initiative.

Tobacco and Health and Certain Other Litigation Items

For the full-year 2025, we recorded pre-tax charges of $58 million (or $0.03 per share) for tobacco and health and certain other litigation items and related interest costs.

For the full-year 2024, we recorded pre-tax charges of $101 million (or $0.04 per share) for tobacco and health and certain other litigation items and related interest costs.

Amortization of Intangibles

In the fourth quarter and full-year 2025, we recorded pre-tax amortization expenses of definite-lived intangible assets of $20 million (or $0.01 per share) and $132 million (or $0.06 per share), respectively.

In the fourth quarter and full-year 2024, we recorded pre-tax amortization expenses of definite-lived intangible assets of $37 million (or $0.01 per share) and $139 million (or $0.07 per share), respectively.

ABI-Related Special Items

In the fourth quarter and full-year 2025, we recorded net pre-tax losses of $59 million (or $0.03 per share) and $95 million (or $0.04 per share), respectively, for ABI-related special items, primarily related to mark-to-market losses on certain ABI financial instruments associated with its share commitments.

In the fourth quarter of 2024, we recorded net pre-tax expenses of $41 million (or $0.02 per share) for ABI-related special items, primarily related to mark-to-market losses and other activities on certain ABI financial instruments associated with its share commitments.

The ABI-related special items included our respective share of the amounts recorded by ABI and additional adjustments related to (i) the conversion of ABI-related special items from international financial reporting standards to GAAP and (ii) adjustments to our investment required under the equity method of accounting.

Income Tax Items

For the fourth quarter and full-year 2024, we recorded income tax items of $928 million (or $0.55 per share) and $969 million (or $0.56 per share), respectively, primarily related to the reversal of an unrecognized tax benefit resulting in the partial release of a valuation allowance related to our former investment in JUUL Labs, Inc. in connection with an agreement reached in October 2024 with the Internal Revenue Service. The amounts for the full-year 2024 also include the partial release of a valuation allowance in connection with the partial sale of our investment in ABI.

SMOKEABLE PRODUCTS

Revenues and OCI

Fourth Quarter

• Net revenues decreased 2.7%, primarily driven by lower shipment volume and higher promotional investments, partially offset by higher pricing. Revenues net of excise taxes decreased 1.1%.
• Reported OCI increased 0.2%, primarily driven by higher pricing and lower costs related to our Initiative, mostly offset by lower shipment volume, higher promotional investments, higher per unit settlement charges and higher costs.
• Adjusted OCI decreased 2.4%, primarily driven by lower shipment volume, higher promotional investments, higher per unit settlement charges and higher costs, partially offset by higher pricing. Adjusted OCI margins decreased by 0.8 percentage points to 60.4%.

Full Year

• Net revenues decreased 3.4%, primarily driven by lower shipment volume and higher promotional investments, partially offset by higher pricing. Revenues net of excise taxes decreased 1.6%.
• Reported OCI increased 1.5%, primarily driven by higher pricing, lower per unit settlement charges and lower tobacco and health and certain other litigation items, partially offset by lower shipment volume and higher promotional investments.
• Adjusted OCI increased 1.3%, primarily driven by higher pricing and lower per unit settlement charges, partially offset by lower shipment volume and higher promotional investments. Adjusted OCI margins increased by 1.8 percentage points to 63.4%.

¹ Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.

Shipment Volume

Fourth Quarter

• Smokeable products segment reported domestic cigarette shipment volume decreased 7.9%, primarily driven by the industry’s decline rate (impacted by the continued growth of illicit e-vapor products and discretionary income pressures on ANCs) and trade inventory movements.
• When adjusted for trade inventory movements, smokeable products segment domestic cigarette shipment volume decreased by an estimated 7%.
• When adjusted for trade inventory movements and other factors, total estimated domestic cigarette industry volume decreased by an estimated 6.5%.
• Reported cigar shipment volume increased 4.2%.

Full Year

• Smokeable products segment reported domestic cigarette shipment volume decreased 10.0%, primarily driven by the industry’s decline rate (impacted by the continued growth of illicit e-vapor products and discretionary income pressures on ANCs), retail share losses and calendar differences.
• When adjusted for calendar differences, smokeable products segment domestic cigarette shipment volume decreased by an estimated 9.5%.
• When adjusted for calendar differences, trade inventory movements and other factors, total estimated domestic cigarette industry volume decreased by an estimated 8%.
• Reported cigar shipment volume increased 1.8%.

Note: Cigarettes volume includes domestic units sold as well as promotional units but excludes units not considered domestic, which are not material to our smokeable products segment.

Retail Share and Brand Activity

Fourth Quarter

• Marlboro retail share of the total cigarette category was 39.8%, a decrease of 1.5 share points versus the prior year and 0.6 share points sequentially. Marlboro share of the premium segment was 59.2%, a decrease of 0.1 share point versus the prior year and 0.4 share points sequentially.
• The cigarette industry discount retail share was 32.9%, an increase of 2.6 share points versus the prior year and 0.7 share points sequentially, primarily due to continued discretionary income pressures on ANCs.

Full Year

• Marlboro retail share of the total cigarette category was 40.5%, a decrease of 1.2 share points. Marlboro share of the premium segment was 59.4%, an increase of 0.1 share point.
• The cigarette industry discount retail share was 31.8%, an increase of 2.2 share points, primarily due to continued discretionary income pressures on ANCs.

Note: Retail share results for cigarettes are based on data from Circana, LLC (Circana) as well as MSAi. Circana maintains a blended retail service that uses a sample of stores and certain wholesale shipments to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes. For other trade classes selling cigarettes, retail share is based on shipments from wholesalers to retailers through the Store Tracking Analytical Reporting System (STARS), as provided by MSAi. This service is not designed to capture sales through other channels, including the internet, direct mail and some tax-advantaged outlets. It is the standard practice of retail services to periodically refresh their retail scan services, which could restate retail share results that were previously released in these services.

ORAL TOBACCO PRODUCTS

Revenues and OCI

Fourth Quarter

• Net revenues increased 2.0%, primarily driven by higher pricing, partially offset by lower shipment volume and a higher percentage of on! shipment volume relative to MST versus the prior year (mix change). Revenues net of excise taxes increased 2.9%.
• Reported OCI decreased 3.3%, primarily driven by higher selling, general and administrative (SG&A) costs, lower shipment volume and mix change, partially offset by higher pricing and lower costs related to our Initiative.
• Adjusted OCI decreased 4.6%, primarily driven by higher SG&A costs, lower shipment volume and mix change, partially offset by higher pricing. Adjusted OCI margins decreased 5.0 percentage points to 64.5%.

Full Year

• Net revenues increased 0.9%, primarily driven by higher pricing, partially offset by lower shipment volume and mix change. Revenues net of excise taxes increased 1.2%.
• Reported OCI increased 26.2%, primarily driven by the 2024 non-cash impairment of the Skoal trademark and higher pricing, partially offset by lower shipment volume, mix change and higher costs.
• Adjusted OCI increased 1.3%, primarily driven by higher pricing, partially offset by lower shipment volume, mix change and higher costs. Adjusted OCI margins increased 0.1 percentage point to 67.9%.

¹ Reported and adjusted OCI margins are calculated as reported and adjusted OCI, respectively, divided by revenues net of excise taxes.

Shipment Volume

Beginning in the first quarter of 2025, our estimated oral tobacco industry volume has been updated for the current and comparable periods to include synthetic oral nicotine pouch products.

Fourth Quarter

• Oral tobacco products segment reported domestic shipment volume decreased 6.3%, primarily driven by retail share losses and trade inventory movements, partially offset by the industry’s growth rate, calendar differences and other factors. When adjusted for trade inventory movements and calendar differences, oral tobacco products segment shipment volume decreased by an estimated 6%.

Full Year

• Oral tobacco products segment reported domestic shipment volume decreased 5.5%, primarily driven by retail share losses, calendar differences and other factors, partially offset by the industry’s growth rate and trade inventory movements. When adjusted for calendar differences and trade inventory movements, oral tobacco products segment shipment volume decreased by an estimated 4.5%.
• Total oral industry volume increased by an estimated 14% for the six months ended December 31, 2025, primarily driven by growth in oral nicotine pouches, partially offset by declines in MST volumes.

Note: Volume includes cans sold, as well as promotional units, but excludes non-domestic volume, which is currently not material to our oral tobacco products segment. New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. To calculate volumes of cans shipped, one can of oral nicotine pouches, irrespective of the number of pouches in the can, is assumed to be equivalent to one can of MST.

Retail Share and Brand Activity

Beginning in the first quarter of 2025, our reported oral tobacco products segment retail share performance data has been updated for the current and comparable periods to include synthetic oral nicotine pouch products. Additionally, in the fourth quarter of 2025, Circana refreshed its retail scan data to account for a retailer data revision that impacted on! and total oral tobacco products retail share data for the second and third quarters of 2025. Restated share results are summarized in Schedule 13.

Fourth Quarter

• Total U.S. oral tobacco category share for on! nicotine pouches was 7.7%, a decrease of 1.0 share point versus the prior year and 0.6 share points sequentially.
• The U.S. nicotine pouch category grew to 56.9% of the U.S. oral tobacco category, an increase of 10.4 share points versus the prior year. In addition, on!’s share of the nicotine pouch category was 13.4%, a decrease of 5.3 share points versus the prior year.

Full Year

• Total U.S. oral tobacco category share for on! nicotine pouches was 8.2%, an increase of 0.1 share point versus the prior year.
• The U.S. nicotine pouch category grew to 53.3% of the U.S. oral tobacco category, an increase of 10.0 share points versus the prior year. In addition, on!’s share of the nicotine pouch category was 15.4%, a decrease of 3.4 share points versus the prior year.

Note: Our oral tobacco products segment’s retail share results exclude non-domestic volume, which is currently not material to our oral tobacco products segment. Retail share results for oral tobacco products are based on data from Circana, a tracking service that uses a sample of stores to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes on the number of cans sold. Oral tobacco products are defined by Circana as domestic oral products, in the form of MST and oral nicotine pouch products (inclusive of tobacco-derived and synthetic oral nicotine products). New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. For example one can of oral nicotine pouches, irrespective of the number of pouches in the can, is assumed to be equivalent to one can of MST. Because this service represents retail share performance only in key trade channels, it should not be considered a precise measurement of actual retail share. It is the standard practice of retail services to periodically refresh their retail scan services, which could restate retail share results that were previously released in these services.

Altria’s Profile

We have a leading portfolio of tobacco products for U.S. tobacco consumers age 21+. We are Moving Beyond Smoking®, by responsibly transitioning adult smokers to a smoke-free future, competing vigorously for existing smoke-free adult nicotine consumers (ANC) and exploring new growth opportunities — beyond the United States and beyond nicotine (Vision). To achieve our Vision, we will pursue initiatives designed to promote the long-term welfare of our company, our stakeholders, society at large and the environment.

Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own Philip Morris USA Inc. (PM USA), the most profitable U.S. cigarette manufacturer, and John Middleton Co. (Middleton), a leading U.S. cigar manufacturer. Our smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), the leading global moist smokeless tobacco (MST) manufacturer, Helix Innovations LLC (Helix), a leading manufacturer of oral nicotine pouches, and NJOY, LLC (NJOY), an e-vapor manufacturer with products covered by marketing granted orders from the U.S. Food and Drug Administration (FDA).

Additionally, we have a majority-owned joint venture, Horizon Innovations LLC (Horizon), for the U.S. marketing and commercialization of heated tobacco stick products.

Our equity investments include Anheuser-Busch InBev SA/NV (ABI), the world’s largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.

The brand portfolios of our operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal®, on!® and NJOY®. Trademarks related to Altria referenced in this release are the property of Altria or our subsidiaries or are used with permission.

Learn more about Altria at www.altria.com and follow us on X, Facebook and LinkedIn.

Basis of Presentation

We report our financial results in accordance with GAAP. Our management reviews OCI, which is defined as operating income before general corporate expenses and amortization of intangibles, to evaluate the performance of, and allocate resources to, our segments. Our management also reviews certain financial results, including OCI, OCI margins and diluted EPS, on an adjusted basis, which excludes certain income and expense items, including those items noted under “2026 Full-Year Guidance.” In addition, our management reviews the ratio of debt-to-Consolidated EBITDA, which we use as a factor to determine our ability to access the capital markets and make investments in pursuit of our Vision. Consolidated EBITDA is calculated in accordance with our credit agreement and contains adjustments. Our management does not view any of these special items to be part of our underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Our management also reviews income tax rates on an adjusted basis. Our adjusted effective tax rate may exclude certain income tax items from our reported effective tax rate. Our management believes that adjusted financial measures provide useful additional insight into underlying business trends and results, and provide a more meaningful comparison of year-over-year results. Our management uses adjusted financial measures for planning, forecasting and evaluating business and financial performance, including allocating capital and other resources and evaluating results relative to employee compensation targets. These adjusted financial measures are not required by, or calculated in accordance with, GAAP and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. We provide reconciliations of historical adjusted financial measures to corresponding GAAP measures in this release.

We use the equity method of accounting for our investments in ABI and Cronos and report our share of ABI’s and Cronos’s results using a one-quarter lag because ABI’s and Cronos’s results are not available in time for us to record them in the concurrent period. The one-quarter reporting lag for ABI and Cronos does not affect our cash flows.

Our reportable segments are (i) smokeable products, consisting of combustible cigarettes and machine-made large cigars, (ii) oral tobacco products, consisting of MST and oral nicotine pouches, and (iii) e-vapor products, consisting of our NJOY business. For the year ended December 31, 2025, we concluded that our e‑vapor products operating segment met the quantitative threshold for presentation as a reportable segment in accordance with GAAP as a result of the non‑cash impairments of e-vapor reporting unit goodwill and related definite-lived intangible assets recorded in 2025. As a result, we presented e-vapor products as a reportable segment (previously in our all other category) and recast segment information for comparative periods. Our all other category included Horizon, Helix International and other business activities, which primarily consists of research and development expense related to certain new product platforms and technologies. Comparisons are to the corresponding prior-year period unless otherwise stated.

Forward-Looking and Cautionary Statements

This release contains projections of future results and other forward-looking statements that are subject to a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

Important factors that could cause actual results to differ materially from those contained in the forward-looking statements included in this release are described in our publicly filed reports, including our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. These factors and risks include the following:

• our inability to anticipate and respond to changes in adult nicotine consumer preferences and purchase behavior;
• our inability to compete effectively;
• the growth of the e-vapor category, including illicit disposable e-vapor products, which contributes to reductions in domestic cigarette consumption levels and shipment volume;
• the impact of illicit trade in nicotine products and the sale of products designed to avoid the regulatory framework for nicotine products, each of which contribute to reductions in the consumption levels and shipment volumes of our businesses’ products;
• our failure to develop and commercialize innovative products, including nicotine products that may reduce health risks relative to other nicotine products and appeal to adult nicotine consumers;
• changes, including in macroeconomic and geopolitical conditions (including inflation and tariffs), that result in shifts in ANC disposable income and purchasing behavior, including choosing lower-priced and discount brands or products, and reductions in shipment volumes;
• unfavorable outcomes with respect to litigation proceedings or any governmental investigations, including significant monetary and non-monetary remedies and importation bans;
• the risks associated with significant federal, state and local government actions, including FDA regulatory actions and inaction, and various private sector actions;
• the risk that regulators, including the FDA, and courts may interpret laws, rules and regulations applicable to our operating companies’ products differently than we do;
• increases in nicotine product-related taxes;
• our failure to complete or manage successfully strategic relationships or transactions, including acquisitions, dispositions, joint ventures, commercial relationships and investments in third parties, or realize the anticipated benefits of such transactions;
• significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of changes in macroeconomic, climate and geopolitical conditions;
• our reliance on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers and the risks associated with an extended disruption at a facility or in service by a supplier, distributor or distribution chain service provider;
• the risk that we may be required to write down goodwill and intangible assets, including trademarks and other intellectual property, due to impairment;
• the risks associated with our Initiative, including risks relating to business continuity, our internal control over financial reporting and audit procedures and our ability to recognize the expected efficiencies;
• the risk that we could decide, or be required, to recall products;
• the various risks related to health epidemics and pandemics and the measures that international, federal, state and local governments, agencies, law enforcement and health authorities implement to address them;
• our inability to attract and retain a highly skilled workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions and other factors;
• the risks associated with the various U.S. and foreign laws and regulations to which we are subject due to our international business operations;
• the risks concerning a challenge to our tax positions, an increase in the income tax rate or other changes to federal or state tax laws;
• the risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters;
• disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets;
• a downgrade or potential downgrade of our credit ratings;
• the impact of heightened focus by investors and other stakeholders on our performance relating to corporate responsibility matters;
• the failure of our, or our key service providers’ or key suppliers’, information systems to function as intended, or cyber-attacks or security breaches affecting us or our key service providers or key suppliers;
• our failure, or the failure of our key service providers or key suppliers, to comply with laws related to personal data protection, privacy, artificial intelligence and information security;
• the risk that the expected benefits of our investment in ABI may not materialize in the expected manner or timeframe or at all; and
• the risks associated with our investment in Cronos, including legal, regulatory and reputational risks and the risk that the expected benefits of the transaction may not materialize in the expected manner or timeframe or at all.

You should understand that it is not possible to predict or identify all factors and risks. Consequently, you should not consider the foregoing list to be complete. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law. All subsequent written and oral forward-looking statements attributable to Altria or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.